Description
N-Acetyl Semax Amidate is a chemically modified variant of the classical Russian nootropic peptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro). The N-terminal acetylation and C-terminal amidation protect the peptide from enzymatic degradation and substantially extend biological half-life vs unmodified Semax.
Per study reports the substance acts like Semax: modulation of BDNF expression in the hippocampus, neuroprotective effects in cerebral ischemia models, modulation of cholinergic and dopaminergic pathways with cognitive-promoting action. Semax was developed at the Russian Institute of Molecular Genetics and is approved in Russia for treatment of stroke rehabilitation and cognitive disorders.
The acetylated and amidated variant brings improved pharmacokinetics with the same pharmacology - exact comparison data between NA variant and parent compound remain limited.
Semax itself is approved in Russia as nasal drops, so the nasal route is the clinically usual one. There are no human data on the acetylated and amidated form itself.
This variant is a ready-to-use nasal spray: 10mg or 30mg of N-Acetyl Semax Amidate dissolved in 5 ml saline and 0.4 ml bacteriostatic water (5.4 ml in total), nothing to mix yourself. One spray (0.1 ml) delivers about 185 mcg, or about 556 mcg in the 30mg variant. A bottle lasts for about 50 sprays. It is made fresh once you place your order and ships as an express item. As a powder for reconstitution, N-Acetyl Semax Amidate remains available in vials.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
N-Acetyl Semax Amidate is considered very well tolerated per study reports. The safety profile follows the parent compound Semax, which has consistently been described as low in side effects across decades of Russian research.
Observed in research and user reports:
- Intranasal irritation: with intranasal use, mild burning, dryness or irritation of the nasal mucosa is the most common observation.
- Stimulation: occasional reports of mild restlessness, head pressure or shifted sleep, particularly with late-day use, as the compound addresses stimulating and cognitive pathways.
- No data on the modified variant: exact comparison data between NA-Semax and the parent compound remain limited. Robust long-term human data on the acetylated and amidated form do not exist.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus - Brain Research 2006, Dolotov et al: shows intranasal Semax raises BDNF protein and trkB phosphorylation in the rat hippocampus.
- Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain - Journal of Neurochemistry 2006, Dolotov et al: binding study and BDNF increase in basal forebrain.
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis - BMC Genomics 2014, Medvedeva et al: genome-wide analysis shows Semax modulates immune and vascular genes in a stroke model.
- Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats - Genes 2020, Filippenkov et al: transcriptome study on neuroprotection after cerebral ischemia.
- Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion - International Journal of Molecular Sciences 2021, Sudarkina et al: proteome analysis confirms the neuroprotective effect in the ischemia-reperfusion model.
